ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: SA-PO908

Intravenous Rituximab vs. Oral Mycophenolate Mofetil in Sustaining Remission in Calcineurin Inhibitor-Dependent Steroid-Resistant Nephrotic Syndrome: An Open-Label Randomized Controlled Trial

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Sinha, Aditi, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bagga, Arvind, All India Institute of Medical Sciences, New Delhi, Delhi, India

Group or Team Name

  • Division of Nephrology, Dept of Pediatrics; Nephrotic Syndrome Study Group.

Retrospective unicenter studies in patients with steroid-resistant nephrotic syndrome (NS) show that switching of calcineurin inhibitors (CNI) to oral mycophenolate mofetil (MMF) or IV rituximab enables remission and is corticosteroid-and CNI-sparing, while avoiding therapy-associated adverse effects (AE). However, prospective controlled studies are lacking.


This open-label multicenter RCT will examine the superiority of IV rituximab versus oral MMF in maintaining satisfactory remission in patients with steroid-resistant NS who were in complete or partial remission while on therapy with tacrolimus or cyclosporine for over 2-yrs, but continued to show steroid-sensitive relapses. Eligible consenting patients with steroid-resistant NS, 1-18 yr-old, with complete or partial remission and steroid sensitive relapses while on ≥2-yr therapy with CNI, will be randomized to switch therapy to either oral MMF for 1-yr or IV rituximab (2 doses a week apart; 1 dose 6-months later). The primary outcome, on intention-to-treat analysis, will be the proportion of patients with satisfactory remission (sustained remission or infrequent relapses) at 1-yr (Fig. 1). Secondary outcomes are the proportions of patients with frequent relapses, steroid resistance & serious AE, incidence of relapses, prednisolone exposure, and changes in anthropometry & biochemistry (CTRI/2022/10/046890).


The study began enrolment in October 2022 and will close enrolment in February 2025.


Findings from the study shall have important implications for guiding the choice of non-nephrotoxic therapies following induction and maintenance of remission with CNI for childhood idiopathic steroid-resistant NS.


  • Government Support – Non-U.S.